Palbociclib · Ibrance

Small molecule

Also known as PD 0332991

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer, HER2-Positive Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Treatment of unresectable or recurrent breast cancer
Product first approved 2017PMDA
EU
  • Locally advanced or metastatic HR-positive, HER2-negative breast cancer, with an aromatase inhibitor or with fulvestrant
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (30)
Breast Cancer
NCT02513394 · Alliance Foundation Trials, LLC.
2015-08 – 2028-12 · Breast Cancer
What this study did
NCT03969121 · Kyoto Breast Cancer Research Network
2019-07-16 – 2021-12-23 · Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
What this study did
NCT03447132 · International Cancer Research Group, United Arab Emirates
2017-12-20 – 2021-07-20 · Breast Neoplasm Female
What this study did
NCT01864746 · GBG Forschungs GmbH
2013-10-30 – 2020-12-21 · Breast Cancer, Hormonreceptor Positive, Her2-normal, Postneoadjuvant Treatment With CDK 4/6 Inhibitor, CPS-EG Score
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06757634 · Celcuity Inc
2025-07-24 – 2033-07-30 · Breast Cancer
What this study did
NCT07683754 · Daiichi Sankyo
2026-11-04 – 2030-08-28 · Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
What this study did
NCT04862663 · AstraZeneca
2021-05-10 – 2029-08-14 · Locally Advanced (Inoperable) or Metastatic Breast Cancer
What this study did
NCT07061717 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-07-01 – 2029-07-01 · Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
What this study did
NCT06065748 · Hoffmann-La Roche
2023-12-11 – 2029-02-12 · Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
What this study did
NCT03820830 · ETOP IBCSG Partners Foundation
2019-08-27 – 2029-01-01 · Breast Cancer Recurrent
What this study did
NCT04964934 · AstraZeneca
2021-06-30 – 2028-09-01 · ER-Positive HER2-Negative Breast Cancer
What this study did
NCT06377852 · American Society of Clinical Oncology
2024-10-29 – 2028-09-01 · Metastatic Breast Cancer
What this study did
NCT04546009 · Hoffmann-La Roche
2020-10-09 – 2028-07-28 · Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
What this study did
NCT05909397 · Pfizer
2023-08-09 – 2026-12-30 · Breast Cancer
What this study did
NCT05207709 · SOLTI Breast Cancer Research Group
2022-03-28 – 2026-03-26 · Metastatic Breast Cancer
What this study did
NCT03079011 · UNICANCER
2017-03-22 – 2025-09-22 · Metastatic Breast Cancer
What this study did
NCT03423199 · National Cancer Center, Japan
2018-02-09 – 2025-09 · Breast Neoplasms
What this study did
NCT04478266 · Sanofi
2020-10-14 – 2023-05-26 · Breast Cancer
What this study did
NCT04047758 · Shengjing Hospital
2019-09-01 – 2022-09-30 · Breast Cancer
What this study did
NCT02028507 · Spanish Breast Cancer Research Group
2014-03-13 – 2021-01-11 · Metastatic Breast Cancer
What this study did
NCT02600923 · Pfizer
2016-04-15 – 2019-05-28 · Advanced Breast Cancer Female
What this study did
Other / comorbidity
NCT04966481 · Washington University School of Medicine
2022-04-06 – 2029-02-28 · HPV-unrelated Head and Neck Squamous Cell Carcinoma
What this study did
NCT03784014 · Institut National de la Santé Et de la Recherche Médicale, France
2019-10-19 – 2026-01-20 · Soft Tissue Sarcoma
What this study did
Phase 2/3 (2)
HR+/HER2- Metastatic Breast Cancer
NCT02692755 · Georgetown University
2016-09 – 2021-03-23 · Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
Other / comorbidity
NCT02785939 · SWOG Cancer Research Network
2014-09 – 2019-06 · CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
What this study did
Phase 2 (131)
Breast Cancer
NCT05069038 · University of Nebraska
2022-03-02 – 2032-09 · Breast Cancer
What this study did
NCT04567420 · Criterium, Inc.
2021-02-09 – 2028-12-31 · Breast Cancer
What this study did
NCT01723774 · Washington University School of Medicine
2013-04-10 – 2027-11-07 · Breast Neoplasms
What this study did
NCT07299890 · Anhui Provincial Cancer Hospital
2025-12-20 – 2027-11-01 · Breast Cancer
What this study did
NCT03573648 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-11-13 – 2027-03-30 · Breast Cancer
What this study did
NCT05067530 · Medical University of Gdansk
2022-01-01 – 2026-12-06 · Triple Negative Breast Neoplasms
What this study did
NCT03609047 · European Organisation for Research and Treatment of Cancer - EORTC
2019-06-14 – 2026-09-30 · Breast Cancer Stage II, Breast Cancer Stage III
What this study did
NCT02760030 · Ohio State University Comprehensive Cancer Center
2017-02-16 – 2025-08-31 · Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
What this study did
NCT04247633 · Samsung Medical Center
2020-02-11 – 2025-02 · Breast Cancer
What this study did
NCT02040857 · Dana-Farber Cancer Institute
2014-01 – 2024-12-27 · Breast Cancer
What this study did
NCT02448420 · SOLTI Breast Cancer Research Group
2015-07 – 2023-11-30 · Metastatic Breast Cancer
What this study did
NCT03065621 · Jules Bordet Institute
2017-07-05 – 2023-02-01 · Breast Cancer Female
What this study did
NCT04075604 · Bristol-Myers Squibb
2019-10-18 – 2021-07-27 · Breast Cancer, Cancer
What this study did
NCT03628066 · NSABP Foundation Inc
2018-10-22 – 2021-01-30 · Breast Cancer
What this study did
NCT02907918 · Washington University School of Medicine
2017-06-30 – 2020-09-23 · Breast Cancer, Cancer of Breast, Breast Carcinoma
What this study did
NCT03819010 · MedSIR
2019-05-07 – 2019-12-31 · Breast Cancer
What this study did
NCT02008734 · Gustave Roussy, Cancer Campus, Grand Paris
2014-01 – 2016-01 · Untreated Operable Early Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT04858516 · Guangdong Provincial People's Hospital
2021-04-30 – 2025-04-30 · Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
What this study did
NCT05076695 · Fudan University
2021-10-15 – 2024-10-15 · Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT02764541 · Dana-Farber Cancer Institute
2016-05-24 – 2031-04 · Breast Cancer
What this study did
NCT04985266 · Royal Marsden NHS Foundation Trust
2022-03-30 – 2030-09-01 · ER+ Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT05564377 · National Cancer Institute (NCI)
2023-04-07 – 2030-07-01 · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT02624973 · Haukeland University Hospital
2016-04-15 – 2030-06 · Breast Cancer
What this study did
NCT05226871 · Pfizer
2022-07-07 – 2029-12-31 · Breast Cancer, Head and Neck Cancer
What this study did
NCT07748208 · Hoffmann-La Roche
2026-11-30 – 2029-09-30 · Breast Cancer, Diabetes Type II
What this study did
NCT04606446 · Pfizer
2020-11-16 – 2029-08-27 · Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT06062498 · Northwestern University
2023-09-29 – 2029-07-01 · Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
What this study did
NCT04220476 · Weill Medical College of Cornell University
2020-03-04 – 2028-12-31 · Breast Cancer
What this study did
NCT04563507 · Weill Medical College of Cornell University
2020-11-12 – 2028-10-31 · Breast Cancer
What this study did
NCT06207734 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2024-01-17 – 2028-07-10 · Breast Cancer
What this study did
NCT02942355 · Wake Forest University Health Sciences
2016-12-07 – 2028-06-30 · Female Breast Carcinoma, Breast Cancer
What this study did
NCT04841148 · Abramson Cancer Center at Penn Medicine
2021-06-01 – 2028-05 · Breast Cancer
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT04920708 · Royal Marsden NHS Foundation Trust
2022-12-28 – 2027-06 · Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
What this study did
NCT04553133 · Pfizer
2020-09-16 – 2026-12-31 · Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
What this study did
NCT03147287 · Dana-Farber Cancer Institute
2017-09-05 – 2026-12-30 · Metastatic Breast Cancer
What this study did
NCT02738866 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016-10-25 – 2026-12 · Metastatic Breast Cancer
What this study did
NCT05766410 · National Taiwan University Hospital
2022-09-16 – 2026-09-30 · Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy
What this study did
NCT05190094 · International Cancer Research Group, United Arab Emirates
2022-12-20 – 2026-06 · Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
What this study did
NCT02778685 · City of Hope Medical Center
2016-09-30 – 2026-03-30 · Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT03633331 · Alliance for Clinical Trials in Oncology
2018-08-15 – 2026-02-27 · Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT04224272 · Jazz Pharmaceuticals
2020-06-10 – 2025-06-30 · HER2+/HR+ Breast Cancer
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT02690480 · Spanish Breast Cancer Research Group
2016-02-17 – 2023-12 · Breast Neoplasms
What this study did
NCT02917005 · Hamdy A. Azim
2019-05-07 – 2023-12 · Metastatic Breast Cancer
What this study did
NCT02630693 · Canadian Cancer Trials Group
2016-04-08 – 2023-11-29 · Breast Cancer
What this study did
Phase 1/2 (44)
Breast Cancer
NCT04494958 · Fundacion Oncosur
2020-11-18 – 2023-12-14 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT05867251 · Avenzo Therapeutics, Inc.
2023-08-30 – 2030-01-31 · Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT04802759 · Hoffmann-La Roche
2021-06-22 – 2029-05-30 · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
What this study did
NCT07861932 · KymaThera, Inc.
2026-10-14 – 2029-03 · Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation
What this study did
NCT05563220 · Stemline Therapeutics, Inc.
2023-01-24 – 2028-12-28 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT07002177 · Forward Pharmaceuticals Co., Ltd.
2025-06-01 – 2028-11-01 · Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Locally Advanced Breast Cancer (LABC), ER+ Breast Cancer
What this study did
NCT03304080 · Icahn School of Medicine at Mount Sinai
2017-12-20 – 2027-12-31 · Breast Neoplasms, Breast Diseases
What this study did
NCT06188520 · AstraZeneca
2023-12-05 – 2027-06-30 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
What this study did
NCT06757335 · Hinova Pharmaceuticals Inc.
2025-01-07 – 2026-11-27 · Breast Cancer
What this study did
NCT02605486 · Memorial Sloan Kettering Cancer Center
2015-11-11 – 2026-11 · Metastatic Breast Cancer (MBC)
What this study did
NCT04072952 · Arvinas Estrogen Receptor, Inc.
2019-09-22 – 2026-03-05 · Breast Cancer
What this study did
NCT04946864 · Ascentage Pharma Group Inc.
2021-08-13 – 2024-10-01 · Breast Cancer, Solid Tumor, Adult
What this study did
NCT03774472 · M.D. Anderson Cancer Center
2018-08-20 – 2024-04-17 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT04669587 · EnhancedBio USA Inc.
2021-07-26 – 2024-01-31 · Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT03054363 · University of Colorado, Denver
2017-11-27 – 2023-02-07 · Breast Cancer
What this study did
NCT03560531 · Zeno Alpha Inc.
2018-11-30 – 2022-12-22 · Breast Cancer
What this study did
NCT02871791 · Dana-Farber Cancer Institute
2016-08-24 – 2021-09 · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
What this study did
NCT02448771 · Dana-Farber Cancer Institute
2015-07-09 – 2021-03-03 · Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
What this study did
NCT03709082 · University of Kansas Medical Center
2018-10-15 – 2021-02-03 · HER2-positive Breast Cancer, Breast Cancer Metastatic
What this study did
Other / comorbidity
NCT07926607 · Second Affiliated Hospital of Nanchang University
2026-11-01 – 2029-12-31 · Acute Myeloblastic Leukemia
What this study did
NCT06753747 · West China Hospital
2025-09-10 – 2028-09 · Esophagus Cancer
What this study did
NCT06843967 · Memorial Sloan Kettering Cancer Center
2025-02-19 – 2028-08-19 · Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Myxoid Pleomorphic Liposarcoma, Pleomorphic Liposarcoma, Unresectable Liposarcoma, Unresectable Dedifferentiated Liposarcoma
What this study did
NCT06940349 · Rabin Medical Center
2021-10-21 – 2028-01-01 · Solid Tumors Refractory to Standard Therapy
What this study did
NCT06736704 · Pikavation Therapeutics, Inc.
2025-02-20 – 2027-06 · Advanced Solid Tumors
What this study did
NCT06947811 · Sun Yat-sen University
2025-06-09 – 2027-03 · EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
What this study did
NCT05468697 · Merck Sharp & Dohme LLC
2022-08-10 – 2026-12-22 · Renal Cell Carcinoma
What this study did
NCT06364956 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-05-15 – 2026-06 · Bladder Cancer
What this study did
NCT05039177 · Erasca, Inc.
2021-09-20 – 2026-01-26 · Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT06895733 · Tianjin Medical University Second Hospital
2024-11-27 – 2025-12-31 · Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine
What this study did
NCT03024489 · Mahidol University
2017-07-19 – 2024-12-31 · Head and Neck Cancer, Locally Advanced
What this study did
NCT05953350 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-11-07 – 2024-12-31 · Inhibition of Autophagy Synergizes Anti-tumor Effect
What this study did
NCT04720768 · Peter MacCallum Cancer Centre, Australia
2020-06-04 – 2024-12-04 · Melanoma, Metastasis
What this study did
NCT03844997 · Sudipto Mukherjee, MD, PhD, MPH
2019-06-06 – 2024-01-24 · Acute Myeloid Leukemia, AML
What this study did
NCT02101034 · Washington University School of Medicine
2014-06-17 – 2023-11-10 · Carcinoma, Squamous Cell of Head and Neck
What this study did
NCT03158389 · University Hospital Heidelberg
2018-05-07 – 2023-02-22 · Glioblastoma, Adult
What this study did
NCT03386929 · Worldwide Innovative Network Association
2017-11-29 – 2022-12-29 · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
What this study did
NCT03965845 · Calithera Biosciences, Inc
2019-06-25 – 2021-09-24 · Solid Tumors, NSCLC, CRC, KRAS Gene Mutation
What this study did
NCT02349633 · Pfizer
2015-05-14 – 2020-05-28 · Non-Small Cell Lung Cancer
What this study did
NCT02310243 · University of Ulm
2015-07 – 2019-07 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
What this study did
NCT02202200 · Assistance Publique - Hôpitaux de Paris
2014-05 – 2018-08 · Melanoma BRAF V600E/K Mutated, CDNKN2A Loss Defined
What this study did
Phase 1 (98)
Breast Cancer
NCT04130152 · SOLTI Breast Cancer Research Group
2019-11-21 – 2022-02-24 · Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT04360941 · Royal Marsden NHS Foundation Trust
2020-08-11 – 2027-07-31 · Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06997029 · Bristol-Myers Squibb
2025-08-01 – 2028-12-14 · Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
What this study did
NCT06941142 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-04-30 – 2028-06 · Advanced Breast Cancer
What this study did
NCT06307249 · Lebanese University
2023-02-15 – 2027-12 · Cancer, Solid Tumor, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Targeted Therapy, Chemotherapy, Immunotherapy, Precision Therapy
What this study did
NCT05683418 · Totus Medicines
2023-02-15 – 2027-12 · HR+/HER2-negative Breast Cancer
What this study did
NCT03959891 · Massachusetts General Hospital
2019-05-30 – 2027-08 · Breast Cancer
What this study did
NCT03616587 · AstraZeneca
2018-10-11 – 2027-06-24 · ER+ HER2- Advanced Breast Cancer
What this study did
NCT05216432 · Relay Therapeutics, Inc.
2021-12-08 – 2027-04-30 · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
What this study did
NCT04288089 · Eisai Inc.
2020-04-01 – 2027-03-31 · Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT06570031 · Ono Pharmaceutical Co., Ltd.
2021-11-09 – 2026-04-30 · Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
What this study did
NCT03900884 · Peter MacCallum Cancer Centre, Australia
2019-09-25 – 2026-03-19 · Breast Neoplasm Female
What this study did
NCT05266105 · Olema Pharmaceuticals, Inc.
2021-12-10 – 2026-03 · Breast Cancer
What this study did
NCT03685331 · Abramson Cancer Center at Penn Medicine
2020-10-15 – 2025-12-01 · Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
What this study did
NCT05293964 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2022-05-18 – 2025-09-08 · Breast Cancer
What this study did
NCT04498520 · Pamela Munster
2021-03-31 – 2025-06-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Endometrioid Adenocarcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Breast Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
What this study did
NCT05759949 · Relay Therapeutics, Inc.
2023-03-29 – 2025-04-11 · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
What this study did
NCT03854903 · Georgetown University
2019-04-01 – 2025-01-09 · Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
What this study did
NCT02499146 · Pfizer
2015-09-11 – 2024-12-24 · Advanced Breast Cancer
What this study did
NCT06065592 · Lebanese University
2019-02-01 – 2024-12 · Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases, Immune System Diseases, Inflammatory Diseases, Colon Cancer, Breast Cancer, Prostate Cancer, Hepatocellular Carcinoma, Lung Cancer, Chemotherapy, Immunotherapy
What this study did
NCT05655598 · Brown University
2023-09-12 – 2024-08-05 · Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
What this study did
NCT05384119 · Tvardi Therapeutics, Incorporated
2023-01-09 – 2024-05-06 · Breast Cancer
What this study did
NCT02913430 · Shannon Puhalla
2018-04-24 – 2024-04-30 · Metastatic Breast Cancer
What this study did
NCT03238196 · Vanderbilt-Ingram Cancer Center
2017-08-18 – 2024-03-20 · Metastatic Breast Cancer
What this study did
NCT02599714 · AstraZeneca
2015-12-07 – 2023-11-23 · Advanced and Metastatic Breast Cancer
What this study did
NCT03471663 · InventisBio Co., Ltd
2018-03-18 – 2023-10-18 · Breast Cancer
What this study did
NCT04818632 · AstraZeneca
2021-11-12 – 2023-09-07 · ER+, HER2-, Metastatic Breast Cancer
What this study did
NCT04872608 · Memorial Sloan Kettering Cancer Center
2021-09-09 – 2023-04-25 · Metastatic Breast Cancer, Unresectable Breast Cancer
What this study did
NCT04483505 · Fundacion CRIS de Investigación para Vencer el Cáncer
2020-11-25 – 2023-04-04 · Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
What this study did
NCT04856371 · Haihe Biopharma Co., Ltd.
2021-04 – 2022-12 · Advanced Breast Cancer
What this study did
NCT03455270 · G1 Therapeutics, Inc.
2018-05-09 – 2022-09-29 · Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
What this study did
NCT03128619 · Jonsson Comprehensive Cancer Center
2017-08-02 – 2022-03-31 · Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT02626507 · Hoffman Oncology
2016-01 – 2022-03-15 · Breast Cancer
What this study did
NCT02897375 · Emory University
2016-10-24 – 2021-10-15 · Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
What this study did
NCT04585724 · Emory University
2020-06-12 – 2021-09-13 · Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT02389842 · Royal Marsden NHS Foundation Trust
2015-03-25 – 2021-05-26 · Advanced Solid Tumours, Breast Cancer
What this study did
NCT01976169 · University of Texas Southwestern Medical Center
2014-01-24 – 2021-05-19 · Advanced Breast Cancer
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01320592 · Abramson Cancer Center at Penn Medicine
2011-03 – 2019-05 · Breast Cancer
What this study did
Other / comorbidity
NCT07787520 · Laekna Limited
2026-08 – 2029-12 · Patients With Advanced Solid Tumors
What this study did
NCT05627232 · Thomas Jefferson University
2023-08-28 – 2029-01 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT06113809 · John Rieth
2024-02-01 – 2028-07 · Sarcoma
What this study did
NCT03454035 · UNC Lineberger Comprehensive Cancer Center
2018-01-30 – 2028-02-03 · Tumor, Solid, Pancreatic Cancer, Melanoma
What this study did
NCT03132454 · M.D. Anderson Cancer Center
2017-07-25 – 2027-12-31 · Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT04693468 · M.D. Anderson Cancer Center
2020-12-01 – 2027-12-31 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
What this study did
Phase 4 (7)
Breast Cancer
NCT04137640 · Shengjing Hospital
2021-07-19 – 2026-05-31 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05949424 · University Medical Center Groningen
2024-05 – 2025-03 · Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma, Endometrium Carcinoma
What this study did
NCT03220178 · Palleos Healthcare GmbH
2017-07-24 – 2021-12-07 · Breast Neoplasm
What this study did
NCT02679755 · Pfizer
2016-03-09 – 2019-07-25 · Breast Cancer
What this study did
Other / comorbidity
NCT05691400 · University of Michigan Rogel Cancer Center
2024-03 – 2027-03 · CYP3A4*22
What this study did
NCT06331715 · Megalabs
2024-02-06 – 2024-05-31 · Bioequivalence
What this study did
Early phase / not applicable (12)
Breast Cancer
NCT06810492 · Hongmei Zheng, PhD
2025-04-01 – 2027-12-01 · Breast Cancer Stage III, Breast Cancer Stage II
What this study did
NCT03756090 · Zhejiang Cancer Hospital
2018-12-01 – 2020-11-30 · Breast Cancer, Breast Diseases, Breast Neoplasms
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04653740 · Centre Oscar Lambret
2020-09-08 – 2027-11 · Advanced Breast Cancer
What this study did
NCT03870919 · UNICANCER
2019-10-23 – 2027-10-23 · Breast Cancer Stage IV, Radiotherapy, Surgery
What this study did
NCT04216576 · Memorial Sloan Kettering Cancer Center
2019-12-27 – 2026-12-27 · Breast Cancer
What this study did
NCT06856200 · Fudan University
2025-02-28 – 2026-06 · Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy
What this study did
NCT05277935 · Beneficência Portuguesa de São Paulo
2022-04-22 – 2025-03-01 · Breast Neoplasm Female, Quality of Life
What this study did
NCT05244434 · City of Hope Medical Center
2022-07-03 – 2023-01-26 · Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Metastatic Breast Adenocarcinoma, Metastatic HER2-Negative Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03401359 · Samsung Medical Center
2017-10-24 – 2022-10-31 · Breast Cancer Stage IV
What this study did
Other / comorbidity
NCT06478927 · Henan Cancer Hospital
2024-01-15 – 2027-01-15 · Hepatocellular Carcinoma
What this study did
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
HR+/HER2- Metastatic Breast Cancer
NCT07894328 · Jiangsu HengRui Medicine Co., Ltd.
2026-11-20 – 2031-09-30 · Breast Cancer
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07174336 · Eli Lilly and Company
2025-12-22 – 2033-05 · Breast Neoplasms, Neoplasm Metastasis
What this study did
Phase 2/3 (1)
Phase 2 (1)
Other / comorbidity
NCT05694871 · Alliance for Clinical Trials in Oncology
2023-06-07 – 2028-04-07 · Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Palbociclib (Ibrance): this drugApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(73 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ibrance (Palbociclib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (14)
November 2026 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT02605486 · CT.gov ↗
What to watch
December 2026 (13)
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2026-12 · NCT04605562 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT02738866 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT03820830 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-22 · NCT05468697 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
Early phase / not applicableHR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT04216576 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT03573648 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05909397 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03006172 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04553133 · CT.gov ↗
What to watch
2027 (29)
January 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-10 · NCT06207734 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm …Recruiting
Est. primary completion 2027-02-20 · NCT06126276 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1/2EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 InhibitorRecruiting
Est. primary completion 2027-03 · NCT06947811 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-04 · NCT06736704 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05216432 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT04920708 · CT.gov ↗
What to watch
Phase 2Well-differentiated/Dedifferentiated LiposarcomaActive not recruiting
Est. primary completion 2027-06 · NCT04438824 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT06188520 · CT.gov ↗
What to watch
July 2027 (6)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-07 · NCT04841148 · CT.gov ↗
What to watch
Phase 1Glioblastoma, Recurrent Disease, Recurrent GlioblastomaEnrolling by invitation
Est. primary completion 2027-07-01 · NCT05432518 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-07-27 · NCT05238922 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT04360941 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03332797 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03304080 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1/2Esophagus CancerRecruiting
Est. primary completion 2027-09 · NCT06753747 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09-01 · NCT04985266 · CT.gov ↗
What to watch
October 2027 (3)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-10 · NCT06941142 · CT.gov ↗
What to watch
Phase 2Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer …Recruiting
Est. primary completion 2027-10-01 · NCT07123090 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-10-31 · NCT04563507 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-11-01 · NCT07299890 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗
What to watch
December 2027 (7)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05683418 · CT.gov ↗
What to watch
Phase 2Esophageal Squamour Cell CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07191977 · CT.gov ↗
What to watch
Phase 1Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia …Active not recruiting
Est. primary completion 2027-12-31 · NCT03132454 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid NeoplasmRecruiting
Est. primary completion 2027-12-31 · NCT04693468 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04567420 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (15)
January 2028 (2)
Phase 1Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01 · NCT05627232 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
February 2028 (2)
Phase 1Tumor, Solid, Pancreatic Cancer, MelanomaRecruiting
Est. primary completion 2028-02-03 · NCT03454035 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04-20 · NCT06065748 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-05-01 · NCT07002177 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-06-30 · NCT02942355 · CT.gov ↗
What to watch
July 2028 (2)
Phase 1SarcomaRecruiting
Est. primary completion 2028-07 · NCT06113809 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-07-01 · NCT06062498 · CT.gov ↗
What to watch
August 2028 (3)
Phase 1/2Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma …Recruiting
Est. primary completion 2028-08-19 · NCT06843967 · CT.gov ↗
What to watch
Phase 2Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8 …Active not recruiting
Est. primary completion 2028-08-26 · NCT05554367 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-31 · NCT06377852 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-09 · NCT07861932 · CT.gov ↗
What to watch
Phase 2Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain MetastasesRecruiting
Est. primary completion 2028-09-01 · NCT02896335 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-14 · NCT06997029 · CT.gov ↗
What to watch
2029 (10)
February 2029 (1)
Phase 3HPV-unrelated Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-02-28 · NCT04966481 · CT.gov ↗
What to watch
March 2029 (2)
Phase 1Patients With Advanced Solid TumorsNot yet recruiting
Est. primary completion 2029-03 · NCT07787520 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-03-31 · NCT06757634 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-06-15 · NCT07748208 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-07-01 · NCT07061717 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08-27 · NCT04606446 · CT.gov ↗
What to watch
December 2029 (3)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloblastic LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07926607 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2029-12-31 · NCT05226871 · CT.gov ↗
What to watch
2030 (4)
July 2030 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch

See the full readout calendar ↗